216 related articles for article (PubMed ID: 25728708)
1. Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.
Vogel CJ; Smit MA; Maddalo G; Possik PA; Sparidans RW; van der Burg SH; Verdegaal EM; Heck AJ; Samatar AA; Beijnen JH; Altelaar AF; Peeper DS
Pigment Cell Melanoma Res; 2015 May; 28(3):307-17. PubMed ID: 25728708
[TBL] [Abstract][Full Text] [Related]
2. A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.
Hayes TK; Luo F; Cohen O; Goodale AB; Lee Y; Pantel S; Bagul M; Piccioni F; Root DE; Garraway LA; Meyerson M; Johannessen CM
Cancer Res; 2019 May; 79(9):2352-2366. PubMed ID: 30819666
[TBL] [Abstract][Full Text] [Related]
3. Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma.
Potu H; Peterson LF; Kandarpa M; Pal A; Sun H; Durham A; Harms PW; Hollenhorst PC; Eskiocak U; Talpaz M; Donato NJ
Nat Commun; 2017 Feb; 8():14449. PubMed ID: 28198367
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Response to Intermittent Binimetinib in Patients with NRAS-Mutant Melanoma.
Matter AV; Micaletto S; Urner-Bloch U; Dummer R; Goldinger SM
Oncologist; 2020 Nov; 25(11):e1593-e1597. PubMed ID: 32886824
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma.
Wei X; Zou Z; Zhang W; Fang M; Zhang X; Luo Z; Chen J; Huang G; Zhang P; Cheng Y; Liu J; Liu J; Zhang J; Wu D; Chen Y; Ma X; Pan H; Jiang R; Liu X; Ren X; Tian H; Jia Z; Guo J; Si L
Eur J Cancer; 2024 May; 202():114008. PubMed ID: 38479118
[TBL] [Abstract][Full Text] [Related]
6. Treatment of severe Kaposiform lymphangiomatosis positive for NRAS mutation by MEK inhibition.
Chowers G; Abebe-Campino G; Golan H; Vivante A; Greenberger S; Soudack M; Barkai G; Fox-Fisher I; Li D; March M; Battig MR; Hakonarson H; Adams D; Dori Y; Dagan A
Pediatr Res; 2023 Dec; 94(6):1911-1915. PubMed ID: 35246606
[TBL] [Abstract][Full Text] [Related]
7. Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma.
Trousil S; Chen S; Mu C; Shaw FM; Yao Z; Ran Y; Shakuntala T; Merghoub T; Manstein D; Rosen N; Cantley LC; Zippin JH; Zheng B
J Invest Dermatol; 2017 May; 137(5):1135-1143. PubMed ID: 28143781
[TBL] [Abstract][Full Text] [Related]
8. A multi-omics integrative approach unravels novel genes and pathways associated with senescence escape after targeted therapy in NRAS mutant melanoma.
Gureghian V; Herbst H; Kozar I; Mihajlovic K; Malod-Dognin N; Ceddia G; Angeli C; Margue C; Randic T; Philippidou D; Nomigni MT; Hemedan A; Tranchevent LC; Longworth J; Bauer M; Badkas A; Gaigneaux A; Muller A; Ostaszewski M; Tolle F; Pržulj N; Kreis S
Cancer Gene Ther; 2023 Oct; 30(10):1330-1345. PubMed ID: 37420093
[TBL] [Abstract][Full Text] [Related]
9. Structural characterization of NRAS isoform 5.
Markowitz J; Mal TK; Yuan C; Courtney NB; Patel M; Stiff AR; Blachly J; Walker C; Eisfeld AK; de la Chapelle A; Carson WE
Protein Sci; 2016 May; 25(5):1069-74. PubMed ID: 26947772
[TBL] [Abstract][Full Text] [Related]
10. Insights Image for "Treatment of severe Kaposiform Lymphangiomatosis positive for NRAS mutation by MEK-inhibition".
Chowers G; Abebe-Campino G; Golan H; Vivante A; Greenberger S; Soudack M; Barkai G; Fox-Fisher I; Li D; March M; Battig MR; Hakonarson H; Adams D; Dori Y; Dagan A
Pediatr Res; 2023 Dec; 94(6):2117. PubMed ID: 37550488
[No Abstract] [Full Text] [Related]
11. Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.
Kemper K; Krijgsman O; Cornelissen-Steijger P; Shahrabi A; Weeber F; Song JY; Kuilman T; Vis DJ; Wessels LF; Voest EE; Schumacher TN; Blank CU; Adams DJ; Haanen JB; Peeper DS
EMBO Mol Med; 2015 Sep; 7(9):1104-18. PubMed ID: 26105199
[TBL] [Abstract][Full Text] [Related]
12. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies.
Johnson DB; Lovly CM; Flavin M; Panageas KS; Ayers GD; Zhao Z; Iams WT; Colgan M; DeNoble S; Terry CR; Berry EG; Iafrate AJ; Sullivan RJ; Carvajal RD; Sosman JA
Cancer Immunol Res; 2015 Mar; 3(3):288-295. PubMed ID: 25736262
[TBL] [Abstract][Full Text] [Related]
13. Rho kinase inhibitors block melanoma cell migration and inhibit metastasis.
Sadok A; McCarthy A; Caldwell J; Collins I; Garrett MD; Yeo M; Hooper S; Sahai E; Kuemper S; Mardakheh FK; Marshall CJ
Cancer Res; 2015 Jun; 75(11):2272-84. PubMed ID: 25840982
[TBL] [Abstract][Full Text] [Related]
14. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
15. Acetylation site specificities of lysine deacetylase inhibitors in human cells.
Schölz C; Weinert BT; Wagner SA; Beli P; Miyake Y; Qi J; Jensen LJ; Streicher W; McCarthy AR; Westwood NJ; Lain S; Cox J; Matthias P; Mann M; Bradner JE; Choudhary C
Nat Biotechnol; 2015 Apr; 33(4):415-23. PubMed ID: 25751058
[TBL] [Abstract][Full Text] [Related]
16. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer.
Pettazzoni P; Viale A; Shah P; Carugo A; Ying H; Wang H; Genovese G; Seth S; Minelli R; Green T; Huang-Hobbs E; Corti D; Sanchez N; Nezi L; Marchesini M; Kapoor A; Yao W; Francesco ME; Petrocchi A; Deem AK; Scott K; Colla S; Mills GB; Fleming JB; Heffernan TP; Jones P; Toniatti C; DePinho RA; Draetta GF
Cancer Res; 2015 Mar; 75(6):1091-101. PubMed ID: 25736685
[TBL] [Abstract][Full Text] [Related]
17. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma.
Welsh SJ; Corrie PG
Ther Adv Med Oncol; 2015 Mar; 7(2):122-36. PubMed ID: 25755684
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.
Garay T; Molnár E; Juhász É; László V; Barbai T; Dobos J; Schelch K; Pirker C; Grusch M; Berger W; Tímár J; Hegedűs B
Pathol Oncol Res; 2015 Sep; 21(4):957-68. PubMed ID: 25749811
[TBL] [Abstract][Full Text] [Related]
19. Treatment of NRAS-mutant melanoma.
Johnson DB; Puzanov I
Curr Treat Options Oncol; 2015 Apr; 16(4):15. PubMed ID: 25796376
[TBL] [Abstract][Full Text] [Related]
20. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
